Matches in Nanopublications for { ?s ?p "[In this issue of Cancer Cell, Fröhling and colleagues tackle this challenge admirably for the known cancer gene FLT3 in acute myeloid leukemia--undertaking a systematic resequencing and functional validation approach, identifying important rare driver mutations as well as passenger mutations in patients negative for the more common activating mutations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 3 of
3
with 100 items per page.
- NP238852.RAukFAQ5Ey5nztNhl-ajMbxFTgombNZmy5GILLfy4OJDI130_assertion description "[In this issue of Cancer Cell, Fröhling and colleagues tackle this challenge admirably for the known cancer gene FLT3 in acute myeloid leukemia--undertaking a systematic resequencing and functional validation approach, identifying important rare driver mutations as well as passenger mutations in patients negative for the more common activating mutations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP238852.RAukFAQ5Ey5nztNhl-ajMbxFTgombNZmy5GILLfy4OJDI130_provenance.
- NP408138.RA9unAXJ2bu2pxoYXZeNsAcxts1GDorwLDKWL0Ck_r7nI130_assertion description "[In this issue of Cancer Cell, Fröhling and colleagues tackle this challenge admirably for the known cancer gene FLT3 in acute myeloid leukemia--undertaking a systematic resequencing and functional validation approach, identifying important rare driver mutations as well as passenger mutations in patients negative for the more common activating mutations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP408138.RA9unAXJ2bu2pxoYXZeNsAcxts1GDorwLDKWL0Ck_r7nI130_provenance.
- NP644369.RAvt646y2dGxSL5EjGZQ25poKa2PlMZ8d6GRkuCTnLu44130_assertion description "[In this issue of Cancer Cell, Fröhling and colleagues tackle this challenge admirably for the known cancer gene FLT3 in acute myeloid leukemia--undertaking a systematic resequencing and functional validation approach, identifying important rare driver mutations as well as passenger mutations in patients negative for the more common activating mutations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP644369.RAvt646y2dGxSL5EjGZQ25poKa2PlMZ8d6GRkuCTnLu44130_provenance.